Meme kanserli kadınlarda adjuvan tamoksifen tedavisinin serum lipid ve lipoprotein düzeylerine etkisi

Abstract

SUMMARY The Effect of Adjuvant Tamoxifen on Serum Lipid and Lipoprotein Levels in Women with Breast Cancer A number of studies have been arranged about the adjuvant Tamoxifen (TAM) therapy in breast cancer for both the therapeutic activity of the drug and the influences on serum lipid and lipoprotein levels, considered as its potential positive side effects. M mis study, the effects of TAM on serum lipids and lipoproteins were compared in both pre- and post-treatment sera and the medical benefits of the results were discussed, A total of 31 women with breast cancer ( 11 premenopausal, 20 postmenopausal ) were included in the study. The serum levels of TC, LDLC, HDLC, TG, APO A-I, APO A-fl, APO B and total estradiol were determined before TAM therapy. After the initiation of TAM ( 10 mg, bid ), the serum levels of the same parameters determined on the 3rd, 6th, 9th and 12th months were all compared to the original results. The serum levels of TC and LDLC decreased in all patients. This decrement was statistically significant (p<0.05). At the end of the study ( 12th month ), the decrement rates of TC and LDLC were 23 % and 43 %, respectively, when compared to the initial levels. While, there were no differences in the serum HDLC levels of the premenopausal group (p>0.05), a statistically significant increment was determined in postmenopausal group (p<0.05). When all cases have been evaluated at the and of the 12th month, we have found that HDLC levels increased 11.6 % and HDLC/TC ratio increased 46 %. When compared to the pretreatment levels, LDLC/HDLC ratio has been found decrease (31 %). There were no statistically significant differences in TG values (p>0.05). v>We have determined that serum APO A-I and APO A-II levels increased (40 %) and APO B levels decreased (22 %) at the end of TAM therapy. When compared to the basal values, APO A-I/APO B ratio has been found to increase (78 %). All these changes have been found to be statistically significant (p<0.05). For the whole length of TAM therapy, while the serum estradiol levels of premenopausal cases showed significant increments (p<0.05), there were no alterations in postmenopausal cases (p>0.05). m the light of these results, we conclude that TAM influences the serum lipid and lipoprotein levels positively, with its partial agonistic effects similar to estrogen. Thus, besides the beneficial effects on breast cancer, TAM prevents the development of coronary heart disease. ?n

SUMMARY The Effect of Adjuvant Tamoxifen on Serum Lipid and Lipoprotein Levels in Women with Breast Cancer A number of studies have been arranged about the adjuvant Tamoxifen (TAM) therapy in breast cancer for both the therapeutic activity of the drug and the influences on serum lipid and lipoprotein levels, considered as its potential positive side effects. M mis study, the effects of TAM on serum lipids and lipoproteins were compared in both pre- and post-treatment sera and the medical benefits of the results were discussed, A total of 31 women with breast cancer ( 11 premenopausal, 20 postmenopausal ) were included in the study. The serum levels of TC, LDLC, HDLC, TG, APO A-I, APO A-fl, APO B and total estradiol were determined before TAM therapy. After the initiation of TAM ( 10 mg, bid ), the serum levels of the same parameters determined on the 3rd, 6th, 9th and 12th months were all compared to the original results. The serum levels of TC and LDLC decreased in all patients. This decrement was statistically significant (p<0.05). At the end of the study ( 12th month ), the decrement rates of TC and LDLC were 23 % and 43 %, respectively, when compared to the initial levels. While, there were no differences in the serum HDLC levels of the premenopausal group (p>0.05), a statistically significant increment was determined in postmenopausal group (p<0.05). When all cases have been evaluated at the and of the 12th month, we have found that HDLC levels increased 11.6 % and HDLC/TC ratio increased 46 %. When compared to the pretreatment levels, LDLC/HDLC ratio has been found decrease (31 %). There were no statistically significant differences in TG values (p>0.05). v>We have determined that serum APO A-I and APO A-II levels increased (40 %) and APO B levels decreased (22 %) at the end of TAM therapy. When compared to the basal values, APO A-I/APO B ratio has been found to increase (78 %). All these changes have been found to be statistically significant (p<0.05). For the whole length of TAM therapy, while the serum estradiol levels of premenopausal cases showed significant increments (p<0.05), there were no alterations in postmenopausal cases (p>0.05). m the light of these results, we conclude that TAM influences the serum lipid and lipoprotein levels positively, with its partial agonistic effects similar to estrogen. Thus, besides the beneficial effects on breast cancer, TAM prevents the development of coronary heart disease. ?n